AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03779906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isovue
Description: Isovue will be given to all subjects per the standard of clinical care.
Study NCT01709604 — intervention group
Intervention type: PROCEDURE
Intervention: CVVH
Description: Ultrafiltration at 35ml/h/Kg
Study NCT01709604 — intervention group
Intervention type: PROCEDURE
Intervention: Standardized therapy regimens
Description: Standardized therapy regimens included the followings:~1. Remove all contaminated clothing~2. Gastric lavage~3. Receive activated charcoal as quickly as possible~4. Hemoperfusion with activated charcoal(160g)~5. Immunosuppression with methylprednisolone~6. Antioxidants (glutathione,1.2 gram iv twice a day)~7. Supportive care
Study NCT06039657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SEAS training
Description: Patients who opted to participate in the SEAS group underwent SEAS therapy. The SEAS therapy program initially comrised patient education and active self-correction. Subsequently, stabilization of active self correction was tried to be performed through various functional activities. These activities were selected from everyday life examples, with increasing levels of difficulty over time. With SEAS exercises, the activation of self-correction was aimed to be increased through various activities in sitting, standing and walking conditions, with the goal of correcting scoliosis in this way
Study NCT06039657 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Patients who declined or were unable to participate in outpatient exercise programs received standard care. Standard care included exercises for postural re-education, traditional strengthening and stretching exercises for one session, followed by observation for one year.
Study NCT01508793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimize Sleep
Description: Children are asked to increase their sleep by approximately 1 1/2 hours/night for the duration of the two month intervention
Study NCT03596255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Estimated level of DA
Description: the dental personnel estimated the patient's level of DA (eDA) on a 100mm VAS
Study NCT03596255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MDAS
Description: The patient rated their DA using the Modified Dental Anxiety Scale (MDAS)
Study NCT03634293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alirocumab Injectable Product
Description: Alirocumab is an human monoclonal antibodies directed against Proprotein convertase subtilisin/kexin type 9 (PCSK9). It is administered once every two weeks subcutaneously.
Study NCT03634293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: The placebo will be 2 ml' of 0.9% saline injected subcutaneously.
Study NCT02813590 — intervention group
Intervention type: OTHER
Intervention: Ascitic fluid puncture
Study NCT02813590 — intervention group
Intervention type: OTHER
Intervention: Skin swaps from puncture side
Study NCT00205881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HiRes 90K Bionic Ear System
Description: Cochlear implant system
Study NCT02574468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone applied on pulp or Dexamethasone did not applied on pulp
Description: on half of cases we put dexamethasone on pulp on other half we did not put dexamethasone on pulp
Study NCT02574468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DPC or MP
Description: on half of cases we treat teeth with DPC(Direct Pulp Cap) on other half we treat teeth with MP(Miniature Pulpotomy)
Study NCT04968301 — intervention group
Intervention type: DEVICE
Intervention: ultrasound Doppler
Description: A cross-sectional study:the development of the hip joint was studied by measuring the anatomical circumference of the capsular muscle of the iliac joint with ultrasound Doppler
Study NCT03910062 — intervention group
Intervention type: PROCEDURE
Intervention: Lower limb angiography via the reperfusion cannula and NIRS monitoring
Description: Data collection only (lower limb angiography, lower limbs NIRS values).
Study NCT03240302 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICSI petri dish
Description: Half of the oocytes will be placed into the standard ICSI petri dish and they will be injected with sperm with normal morphology.
Study NCT03240302 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICSI petri dish
Description: Half of the oocytes will be placed into a PICSI petri dish (whose bottom is coated with hyaluronic acid) and the mature spermatozoa with CD44 receptors that are attached to the bottom of the dish will be injected into them.
Study NCT03244215 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Corneal Confocal Imaging
Description: Retinal imaging will be ordered for all subjects in the study group. Corneal
Study NCT02813590 — intervention group
Intervention type: OTHER
Intervention: Stool samples
Study NCT01560104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Study NCT01560104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Study NCT01560104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01560104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Study NCT01560104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT01560104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01786434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine medication arm
Description: 50 micrograms of fentanyl given before the procedure
Study NCT01786434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl on-demand arm
Description: Fentanyl 50 microgram is provided on-demand, that is, if the patient has pain during the procedure.
Study NCT00859573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: 400 mg/day
Study NCT00859573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive substance
Study NCT00653068 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT
Study NCT00653068 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSC rescue
Study NCT00653068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00653068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00653068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00653068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT00653068 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV or SC
Study NCT00653068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00653068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV or PO
Study NCT00653068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT00653068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study NCT00653068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03244215 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance Imaging
Description: MRI will be ordered for all study subjects at the completion of their participation at year 1. The MRI will assess the the progression or regression of the cerebrovascular health of the study subjects.
Study NCT03244215 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood samples will be obtained to evaluate the levels of blood inflammatory biomarkers in both the subjects and control group.
Study NCT03244215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood samples will be obtained to evaluate the levels of blood inflammatory biomarkers in both the subjects and control group.
Study NCT04960501 — intervention group
Intervention type: PROCEDURE
Intervention: New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella
Description: New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella
Study NCT00888862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate
Description: Desvenlafaxine Succinate, 50-100mg/day for 8 weeks
Study NCT02925494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/Norethindrone Acetate
Description: capsules
Study NCT02925494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: film-coated tablets
Study NCT03636061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-01 (varenicline) nasal spray
Description: OC-01 (varenicline) nasal spray
Study NCT02180568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipiodol
Description: Lipiodol-guided lung localization technique
Study NCT02180568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hookwire
Description: Hookwire-guided lung localization technique
Study NCT02180568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipiodol
Study NCT01305941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: everolimus 5 mg PO daily as two 2.5-mg tablets
Study NCT01305941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: vinorelbine 25 mg/m2 will be administered via IV infusion over 6-10 minutes weekly.
Study NCT03636061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle) nasal spray
Description: Placebo
Study NCT01927510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early mobilisation
Study NCT01305941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 2 mg/kg IV administered over 30 minutes weekly
Study NCT01683383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device (servo-regulated cooling)
Description: Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
Study NCT01683383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (standard practice)
Description: Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
Study NCT01816386 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture Regimen
Description: Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press needles (with a sharp tip) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
Study NCT02601378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXS196
Description: LXS196 as a single agent
Study NCT02601378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXS196 and HDM201
Description: LXS196 in combination with HDM201
Study NCT00880009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 400mg (4x100)mg tablets once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
Study NCT00880009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
Study NCT00880009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
Study NCT01816386 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupressure Regimen
Description: Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press plasters (with a blunt knob instead a sharp needle) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
Study NCT01736163 — intervention group
Intervention type: DRUG
Intervention: Thyrogen
Description: 0.9 mg IM, administrated for 2 consecutive days
Study NCT01736163 — intervention group
Intervention type: DRUG
Intervention: 131I
Description: 28 mCi or ≥ 1.036 GBq.
Study NCT01736163 — intervention group
Intervention type: OTHER
Intervention: Thyroid Hormone Withdrawal
Description: Stop taking hormone therapy
Study NCT01428986 — intervention group
Intervention type: DRUG
Intervention: Maraviroc
Description: Maraviroc, 300mg BID for 72 weeks, except for cases with Efavirenz or Etravirine, 600mg BID for 72 weeks
Study NCT03556072 — intervention group
Intervention type: OTHER
Intervention: Routine ERCP
Study NCT02469922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography
Study NCT02469922 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy
Description: Every patients will be treated with radiochemotherapy as a standard of care
Study NCT01745133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle foam
Description: clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
Study NCT01745133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcipotriene
Description: clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks
Study NCT01745133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcipotriene + clobetasol propionate
Description: clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
Study NCT03972332 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Sensory Testing
Description: PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT).
Study NCT02771093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trelagliptin
Description: Trelagliptin 100 mg tablet
Study NCT02771093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg tablet
Study NCT01651247 — intervention group
Intervention type: PROCEDURE
Intervention: Serum sample
Description: Serum samples collected at pre-determined time points in previously completed studies (217744/085 and 213503/048) will be analysed to detect the presence of anti PCV-1 antibodies.
Study NCT00681005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabeprazole
Description: 20 mg bid for 14 days
Study NCT00681005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole
Description: pantoprazole 40 mg bid
Study NCT00291577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib (Sutent)
Description: Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision
Study NCT00291577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Taxotere 75 mg/m2 iv, once every 3 weeks
Study NCT03954236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical ruxolitinib 1.5% cream
Description: Patients will be prescribed twice daily use of topical ruxolitinib 1.5% cream (randomized half of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days. Topical ruxolitinib will be provided as topical cream. At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
Study NCT03954236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical vehicle/moisturizer cream
Description: Patients will be prescribed twice daily use of vehicle/moisturizer (for contralateral side of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days.At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
Study NCT00830362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: 40 mg administered once
Study NCT00830362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered once
Study NCT01365910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linifanib
Description: Given PO
Study NCT01587001 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl-cysteine
Description: 900mg three times daily for 8 weeks
Study NCT01587001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo three times daily for 8 weeks.
Study NCT01781143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perform Echo at home.
Description: A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
Study NCT00834171 — intervention group
Intervention type: DRUG
Intervention: Loteprednol etabonate ophthalmic suspension 0.5%
Description: Apply one to two drops of Loteprednol etabonate ophthalmic suspension 0.5% into the conjunctival sac as prescribed by your physician
Study NCT00834171 — intervention group
Intervention type: DRUG
Intervention: Loteprednol etabonate (0.5%) and tobramycin (0.3%).
Description: Apply one or two drops of Loteprednol etabonate (0.5%) and tobramycin (0.3%) into the conjunctival sac as prescribed by your physician.
Study NCT00554528 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: cervical disc prosthesis with a mobile insert named Mobi-C
Description: Stage 1: partial discectomy~stage 2: location of the medial axis~stage 3: centering pin~stage 4: installation of the caspar spacer~stage 5: total discectomy~stage 6: parallel distraction~stage 7: depth measurement~stage 8: trial implant~stage 9: assembly~stage 10: implant insertion~stage 11: anchorage optimization
Study NCT00554528 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: arthrodesis - cervical disk surgery
Description: discectomy and arthrodesis
Study NCT00828659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00828659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator #1
Study NCT00828659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator #2
Study NCT00828659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator #3
Study NCT00828659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin Dose #1
Study NCT00828659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin Dose #2
Study NCT00828659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin Dose #3
Study NCT01486667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxine
Description: Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of levothyroxine. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.